Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dovitinib in FGFR2-amplified Gastric Cancer
NCT01719549Phase 2Completed
- Sponsor
- Asan Medical Center
- Start
- Sep 2012
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dovitinib in gastric cancer (GC), sponsored by Asan Medical Center. Primary endpoints: Overall Response Rate at 1 year and Progression-Free Survival at 2 years. Started Sep 2012; status: completed.
02
Drugs
dovitinib
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT01719549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01719549.